To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Blood reviews

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.blre.2017.07.001PMID 28716211
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization.

  2018cited by this paper
• Navigating Speed Bumps on the Innovation Highway in Hemophilia Therapeutics

  2018cited by this paper
• Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa)

  2017cited by this paper
• The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells

  2017cited by this paper
• SIPPET: methodology, analysis and generalizability

  2017cited by this paper
• Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs

  2017cited by this paper
• Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients.

  2016cited by this paper
• Von Willebrand's Disease.

  2016cited by this paper
• von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII

  2016cited by this paper
• T follicular regulatory cells

  2016cited by this paper
• A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

  2016cited by this paper
• Hunting down factor VIII in the immunopeptidome.

  2016cited by this paper
• Dissecting intensive treatment as risk factor for inhibitor development in haemophilia

  2016cited by this paper
• B-cell memory against factor VIII.

  2016cited by this paper
• Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII

  2016cited by this paper
• The alpha-gal story: lessons learned from connecting the dots.

  2015cited by this paper
• von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends.

  2015cited by this paper
• To clear or to fear: An innate perspective on factor VIII immunity

  2015cited by this paper
• Factor VIII Interacts with the Endocytic Receptor Low-density Lipoprotein Receptor-related Protein 1 via an Extended Surface Comprising “Hot-Spot” Lysine Residues♦

  2015cited by this paper
• US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors

  2015cited by this paper
• FVIII-VWF dos-à-dos.

  2015cited by this paper
• Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry.

  2015cited by this paper
• Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII.

  2015cited by this paper
• Lgr4 and Lgr5 drive the formation of long actin-rich cytoneme-like membrane protrusions

  2015cited by this paper
• Genome-wide association studies identify genetic loci for low von Willebrand factor levels

  2015cited by this paper
• Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein.

  2015cited by this paper
• Endo-lysosomal proteases in antigen presentation.

  2014cited by this paper
• The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A

  2014cited by this paper
• Risky business of inhibitors: HLA haplotypes, gene polymorphisms, and immune responses.

  2014cited by this paper
• Primary haemostasis: newer insights

  2014cited by this paper
• Inhibitors – genetic and environmental factors

  2014cited by this paper
• Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review

  2014cited by this paper
• Second‐generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A

  2014cited by this paper
• A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

  2014cited by this paper
• Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII.

  2013cited by this paper
• Guidelines for the management of hemophilia

  2013cited by this paper
• The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters

  2013cited by this paper
• Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)

  2013cited by this paper
• Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.

  2013cited by this paper
• Dangerous liaisons: how the immune system deals with factor VIII

  2013cited by this paper
• Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.

  2013cited by this paper
• The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels.

  2013cited by this paper
• The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

  2013cited by this paper
• Factor VIII C1 Domain Spikes 2092–2093 and 2158–2159 Comprise Regions That Modulate Cofactor Function and Cellular Uptake

  2013cited by this paper
• Factor VIII products and inhibitor development in severe hemophilia A.

  2013cited by this paper
• Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter

  2013cited by this paper
• Characterization of tyrosine sulphation in rFVIII (turoctocog alfa) expressed in CHO and HEK‐293 cells

  2012cited by this paper
• Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells.

  2012cited by this paper
• Past, present and future of hemophilia: a narrative review

  2012cited by this paper
• Integrative Physiology/Experimental Medicine Identification of Galectin-1 and Galectin-3 as Novel Partners for Von Willebrand Factor

  2012cited by this paper
• Macrophage LRP1 contributes to the clearance of von Willebrand factor.

  2012cited by this paper
• Mapping the N-glycome of human von Willebrand factor.

  2012cited by this paper
• Sequence and structure relationships within von Willebrand factor.

  2012cited by this paper
• The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics

  2012cited by this paper
• Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.

  2012cited by this paper
• Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5

  2012cited by this paper
• Octocog Alfa, Antihaemophilic Factor (Recombinant), Plasma/Albumin Free Method (Advate®)

  2012cited by this paper
• Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain.

  2012cited by this paper
• Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.

  2012cited by this paper
• Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells Reply

  2012cited by this paper
• Incomplete tyrosine 1680 sulphation in recombinant FVIII concentrates

  2011cited by this paper
• C1 domain residues Lys 2092 and Phe 2093 are of major importance for the endocytic uptake of coagulation factor VIII.

  2011cited by this paper
• von Willebrand disease

  2011cited by this paper
• Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels

  2011cited by this paper
• The International Society on Thrombosis and Haematosis von Willebrand Disease Database: An Update

  2011cited by this paper
• An improved manufacturing process for Xyntha/ReFacto AF

  2010cited by this paper
• Factor VIII and von Willebrand factor – too sweet for their own good

  2010cited by this paper
• Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

  2010cited by this paper
• Chinese hamster ovary cells can produce galactose-α-1,3-galactose antigens on proteins

  2010cited by this paper
• Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review

  2010cited by this paper
• The Multifactorial Etiology of Inhibitor Development in Hemophilia: Genetics and Environment

  2009cited by this paper
• Splenic marginal zone antigen‐presenting cells are critical for the primary allo‐immune response to therapeutic factor VIII in hemophilia A

  2009cited by this paper
• Risk factors for inhibitor formation in haemophilia: a prevalent case–control study

  2009cited by this paper
• Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease

  2009cited by this paper
• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

  2008cited by this paper
• General introduction and outline of the thesis

  2008cited by this paper
• The role of VWF for the success of immune tolerance induction.

  2008cited by this paper
• Immunogenicity of factor VIII concentrates in patients with hemophilia: a randomized clinical trial is warranted.

  2007cited by this paper
• International workshop on immune tolerance induction: consensus recommendations 1

  2007cited by this paper
• Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

  2007cited by this paper
• A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes

  2007cited by this paper
• IgE‐mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A

  2007cited by this paper
• VWF/FVIII concentrates in high‐risk immunotolerance: the RESIST study

  2007cited by this paper
• Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins

  2007cited by this paper
• VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

  2007cited by this paper
• Dynamics and Plasticity of Weibel-Palade Bodies in Endothelial Cells

  2006cited by this paper
• Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

  2006cited by this paper
• Proteolytic cleavage of factor VIII heavy chain is required to expose the binding‐site for low‐density lipoprotein receptor‐related protein within the A2 domain

  2006cited by this paper
• Staphylococcus aureus: the search for novel targets.

  2005cited by this paper
• The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor

  2005cited by this paper
• Reported inhibitor incidence in FVIII PUP studies: comparing apples with oranges?

  2004cited by this paper
• Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency.

  2003cited by this paper
• Presence of Gal‐α1,3Gal epitope on xenogeneic lines: implications for cellular gene therapy based on the encapsulation technology

  2003cited by this paper
• The epidemiology of inhibitors in haemophilia A: a systematic review

  2003cited by this paper
• An adventure in biotechnology: the development of haemophilia A therapeutics – from whole‐blood transfusion to recombinant DNA to gene therapy

  2002cited by this paper
• Safety and efficacy of KOGENATE® Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs)

  2002cited by this paper
• bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use

  2002cited by this paper
• Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology.

  2001cited by this paper
• Effect of intermediate‐purity factor VIII (FVIII) concentrate on lymphocyte proliferation and apoptosis: transforming growth factor‐β is a significant immunomodulatory component of FVIII

  2001cited by this paper
• Definitions in Hemophilia

  2001cited by this paper

• A comprehensive review of the autoimmune pathogenesis of acquired hemophilia A.

  2025cites this paper
• Identification of the Efficient Enhancer Elements in FVIII-Padua for Gene Therapy Study of Hemophilia A

  2024cites this paper
• Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A.

  2023cites this paper
• Mutation detection and inhibitor analysis of 43 children with severe hemophilia A in a single center: three novel mutations

  2023cites this paper
• No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients

  2023cites this paper
• Plasma‐derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study

  2022cites this paper
• Modified expi293 cell culture system using piggyBac transposon enables efficient production of human FVIII

  2022cites this paper
• Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products

  2021cites this paper
• Structural and Mutational Characterization of the Blood Coagulation Factor VIII C Domain Lipid Binding Interface

  2021cites this paper
• Tolerogenic form of Factor VIII to prevent inhibitor development in the treatment of Hemophilia A

  2021cites this paper
• Structure of Blood Coagulation Factor VIII in Complex with Anti-C2 Domain Inhibitory Antibody

  2021cites this paper
• Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor

  2021cites this paper
• Immune Responses to Plasma-Derived Versus Recombinant FVIII Products

  2021cites this paper
• Factor VIII Fc Fusion Protein but not FVIII Drives Human Monocyte-Derived Dendritic Cell Activation via FcγRIIa

  2020cites this paper
• Quantitative HLA‐class‐II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A

  2020cites this paper
• Hemocytin facilitates host immune responses against Nosema bombycis.

  2020cites this paper
• Tolerating Factor VIII: Recent Progress

  2020cites this paper
• Functional identification of factor VIII B domain regions in hepatocyte cells.

  2020cites this paper
• A molecular jewel for hemophilia A treatment.

  2020cites this paper
• Developing BIVV001, a new class of factor VIII replacement for hemophilia A that is von Willebrand factor-independent.

  2020cites this paper
• von Willebrand Disease, A Rare Cause of Massive Upper GI Bleeding: A Case Report

  2020cites this paper
• Antibodies in the Treatment of Haemophilia A—A Biochemical Perspective

  2019cites this paper
• The role of variant alleles of the mannose-binding lectin in the inhibitor development in severe hemophilia A.

  2019cites this paper
• Sensitivity improved with Parylene-C passivized on Lamb wave sensor for aPTT measurement through monitoring whole blood reaction

  2019cites this paper
• Navigating Speed Bumps on the Innovation Highway in Hemophilia Therapeutics

  2018cites this paper
• Factor VIII manufactured from plasma—the ups and downs, and the up again: a personal journey—part 1: history of the development of plasma-derived factor VIII therapies

  2018cites this paper
• Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization.

  2018cites this paper
• Hemophilia: past, present, and future

  2018cites this paper
• Von Willebrand factor contribution to pathophysiology outside of von Willebrand disease

  2018cites this paper
• A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation.

  2018cites this paper
• Anti‐C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model

  2018cites this paper
• SIPPET: insights into factor VIII immunogenicity

  2018cites this paper
• Immunogenic Determinants of Coagulation Factor VIII

  2018cites this paper
• Risk factors for inhibitor development in severe hemophilia a.

  2018cites this paper
• Unexpectedly high response to DDAVP in two patients with moderate haemophilia A

  2018cites this paper
• Congenital Hemophilia A Presenting With Hashimoto's Encephalopathy and Myocarditis: The First Reported Case.

  2017cites this paper